North America Coagulation Market

The North America coagulation market was valued at US$ 2,712.64 million in 2022 and is expected to reach US$ 4,633.26 million by 2030; it is estimated to grow at a CAGR of 6.9% from 2022 to 2030.

Increasing Prevalence of Blood Disorders Fuel North America Coagulation Market

Hemophilia A is one of the common X-linked recessive disorders and the second most common inherited clotting factor deficiency after von Willebrand disease, according to the National Organization of Rare Disorders. Also, ~1 in 5,000 male infants suffers from hemophilia A in the US. According to the Global Hemophilia Care 2020 study, 393,658 bleeding disorders cases have been recognized and documented worldwide over time, including 241,535 hemophilia cases, 87,729 von Willebrand disease cases, and 64,394 other bleeding disorder cases. According to the National Library of Medicine (NLM), ~30,000-33,000 men were affected by hemophilia in the US in 2020.

As per the reports from the American Cancer Society (CLL), the US recorded ~21,250 new cases of chronic lymphocytic leukemia in 2021. A February 2020 update from the Centers for Disease Control and Prevention (CDC) states that the number of people in the US affected by deep vein thrombosis could reach 900,000 (1 to 2 per 1,000). The same source estimates that in the US 60,000-100,000 Americans die yearly from venous thromboembolism.

According to the US Department of Health & Human Services, ~100,000 Americans were diagnosed with sickle cell disease (SCD) in 2020, which is one of the most commonly inherited blood disorders. In addition, the number of people suffering from SCD is expected to grow by ~30% by 2050. The National Organization for Rare Disorders stated that immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affected ~66 adults per 1 million in the US each year in 2022. Therefore, the rising prevalence of blood disorders drives the coagulation market growth.

North America Coagulation Market Overview

The North America coagulation market is segmented into the US, Canada, and Mexico. North America accounts for a significant market share owing to the growing incidences of blood disorders, increasing occurrence of cardiovascular diseases such as atrial fibrillation (AFib), and the presence of major market players engaged in new and existing product developments. The US holds the largest share of the coagulation market in North America. The burgeoning cases of blood disorders, growing prevalence of cardiovascular diseases, and government support for preventing blood disorders are anticipated to boost the North America coagulation market growth during 2022-2030.

North America Coagulation Market Revenue and Forecast to 2030 (US$ Million)

North America Coagulation Market Segmentation

The North America coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the North America coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest North America coagulation market share in 2022.

Based on type, the North America coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger North America coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the North America coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger North America coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the North America coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest North America coagulation market share in 2022.

By end user, the North America coagulation market is segmented into clinical laboratories, hospitals, and others. The clinical laboratories segment held the largest North America coagulation market share in 2022.

Based on country, the North America coagulation market is categorized into the US, Canada, and Mexico. The US dominated the North America coagulation market in 2022.

Diagnostica Stago Inc, F Hoffmann-La Roche Ltd, Genrui Biotech Co, Ltd, Helena Laboratories Corporation, Horiba Ltd, ImproGen Diagnostik Kimya San. & Tic. Ltd ?ti, Siemens Healthineers AG, Sysmex Corp, and Transasia Bio-Medicals Ltd are some of the leading companies operating in the North America coagulation market.

North America Coagulation Strategic Insights

Strategic insights for the North America Coagulation provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Coagulation Report Scope

North America Coagulation Regional Insights

The geographic scope of the North America Coagulation refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.